Maravai shares rise 11.85% after-hours following CEO's major stock purchase.

Maravai LifeSciences Holdings surged 11.85% in after-hours trading following the announcement that its CEO executed a major stock purchase, signaling confidence in the company’s strategic direction. The move, described as "bold," suggests management’s belief in the company’s long-term value despite a reported Q3 2025 revenue decline to $41.6 million from $69 million in the prior year. While the earnings report highlighted weaker revenue, the CEO’s purchase likely overshadowed near-term concerns, driving investor optimism about potential cost-cutting measures or operational improvements. The after-hours rally reflects renewed market confidence in the company’s ability to stabilize its performance under leadership’s renewed commitment.